NEW BRUNSWICK, N.J. / Dec 07, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8th, at the Westin St. Francis in San Francisco, CA. Joaquin Duato, Chairman and Chief Executive Officer will represent the Company in a session scheduled at 12:45 p.m. (Eastern Time)
This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.
The audio webcast replay will be available approximately 48-hrs after the webcast.
| Last Trade: | US$145.58 |
| Daily Change: | -0.27 -0.19 |
| Daily Volume: | 4,233,700 |
| Market Cap: | US$350.850B |
December 09, 2024 December 08, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
